secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0001823239-23-000012
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai Q4 revenue $204.7M, adj EPS $0.35; 2023 guidance $420-460M; acquires Alphazyme
--------------------------------------------------------------------------------

- Q4 revenue $204.7M (-10% YoY); net income $87.4M; adjusted diluted EPS $0.35.
- Full year 2022 revenue $883.0M (+10% YoY); net income $490.7M; adjusted EPS $1.80.
- Base business revenue (ex-COVID CleanCap) up 67% in Q4 and 17% full year.
- 2023 revenue guidance $420M-$460M; base business growth expected >20%.
- Acquired Alphazyme, LLC (private enzyme manufacturer); announced CEO succession plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323923000012/0001823239-23-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323923000012/mrvi-20230222.htm
  HTML page:      https://secwatch.observer/filing/0001823239-23-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer